Company / Free Cash Flow
Viridian Therapeutics, Inc.\DE Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$276.9M
FY2025
5-year range
-$276.9M / -$54.9M
FY2021-FY2025
Trend
-18.9%
vs FY2024
Sector context
#165 of 194
Health Care
What the data says
Viridian Therapeutics, Inc.\DE's free cash flow of -$277M is lower than 85% of companies in the Health Care sector (FY2025). Free Cash Flow has declined for 5 consecutive years, from -$30M in FY2020 to -$277M in FY2025.
Based on SEC 10-K filings.
-$277M in FY2025.
Declined from -$185M to -$277M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 194This company -$276.9M Sector average $470.6M
▼
-158.8% below sector average
Key checks
Key Insights
- Viridian Therapeutics, Inc.\DE's free cash flow has declined for 5 consecutive years.
- In FY2025, free cash flow decreased 18.9% year-over-year.
- Ranks #165 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$276.9M | -18.9% |
| FY2024 | -$232.8M | -25.8% |
| FY2023 | -$185.1M | -95.6% |
| FY2022 | -$94.6M | -72.3% |
| FY2021 | -$54.9M | -84.2% |
| FY2020 | -$29.8M | +17.5% |
| FY2019 | -$36.1M | -32.4% |
| FY2018 | -$27.3M | +4.0% |
| FY2017 | -$28.4M | -89.4% |
| FY2016 | -$15.0M | -113.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026